Evome Medical Technologies Inc. (LNDZF) Stock Price & Analysis
Evome Medical Technologies Inc. (LNDZF) — price $0.0001 (0.00%), as of the Oct 2, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Evome Medical Technologies Inc. · LNDZF
Evome Medical Technologies Inc. develops, manufactures, and distributes medical devices for pain management and physical therapy. The company operates in the Americas and internationally, offering a diverse product portfolio including isokinetic dynamometers, gait trainers, and electrical stimulation devices.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.0001 | |
| Change on the day | 0.00% | |
| 52-week range | $0.0001 – $0.006 | |
| Shares traded on the day | 10.0K |
Price & events
Other perspectives
Council score for Evome Medical Technologies (LNDZF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 5, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the LNDZF film — every key number, told as a short cinematic story
~2 min · open the film
What is Evome Medical Technologies (LNDZF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Evome Medical Technologies Inc. (LNDZF) is the company analyzed here. It employs 195 people and is led by Christopher Heath. In Q3 FY2024 it reported revenue of $7M and net income of -$806,479.247.
What do the latest results show for Evome Medical Technologies (LNDZF)?
Short answer · as of
The most recent reported quarter, Q3 FY2024, carried revenue of $7M.
Quarterly income statement — 3 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2024 | $7M | -$806,479.247 | -$0.01 (diluted) |
| Q2 FY2024 | $7M | -$2M | -$0.02 (diluted) |
| Q1 FY2024 | $8M | -$3M | -$0.03 (diluted) |
What are the financial strengths and risks for Evome Medical Technologies (LNDZF)?
Short answer
The distress and quality screens read Altman Z -3.77 · Piotroski F 4. Trailing ratios: ROE -44.2% · ROA -10.2% · current ratio 0.87 · earnings yield -45.6% · free-cash-flow yield -21.8%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -3.77 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-44.2%) — the business is not currently generating profit on shareholder capital.
The records behind this page
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 3
- Identified insiders
- 2
- Purchases
- 2
- Sales
- 0
- Other transactions
- 1
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Investor Questions: LNDZF Stock
These answers are editorial: 1 of these 1 answer is drawn from the LNDZF research dossier (written Mar 16, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.
How does Evome Medical Technologies Inc. navigate regulatory approval processes?
Evome Medical Technologies Inc. must adhere to stringent regulatory requirements set by agencies such as the FDA in the United States and similar bodies in international markets.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (13 figures)
The 13 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 8 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $0.0001 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T10:44:41.667Z. | |
px.change | Change on the day | 0.00% | FMP | Financial Modeling Prep (FMP) · quote | |
px.change_abs | Change on the day, in dollars | $0.00 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 10.0K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q3 FY2024 | $7M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q3 FY2024 | -$806,479.247 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 3 quarters through Q3 FY2024 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
own.insiders | Insider transactions via FMP | 3 transactions · 2 purchases, 0 sales, 1 other transactions · 2 identified insiders · most recent available transactions | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. |
UNRECORDED — 5 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $0.0001 – $0.006 | UNRECORDED | Stored company-profile observation — Captured 2026-09-23 · Expired observation | |
id.employees | Employees | 195 | UNRECORDED | Stored company-profile observation — Captured 2026-09-23 · Expired observation | |
id.ceo | Chief executive | Christopher Heath | UNRECORDED | Stored company-profile observation — Captured 2026-09-23 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z -3.77 · Piotroski F 4 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-05 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -44.2% · ROA -10.2% · current ratio 0.87 · earnings yield -45.6% · free-cash-flow yield -21.8% | — | UNRECORDED | Stored key metrics — Date unknown |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.